Atea Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
AVIR$4.41+2.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $87,721 | $64,696 |
| Marketable securities | 291,992 | 390,025 |
| Prepaid expenses and other current assets | 5,891 | 7,634 |
| Total current assets | 385,604 | 462,355 |
| Property and equipment, net | 665 | 873 |
| Other assets | 4,394 | 197 |
| Operating lease right-of-use assets, net | 942 | 1,243 |
| Total assets | $391,605 | $464,668 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $8,844 | $4,458 |
| Accrued expenses and other current liabilities | 10,454 | 13,345 |
| Current portion of operating lease liabilities | 821 | 800 |
| Total current liabilities | 20,119 | 18,603 |
| Operating lease liabilities | 425 | 842 |
| Income taxes payable | 6,645 | 6,356 |
| Total liabilities | 27,189 | 25,801 |
| Commitments and contingencies (see Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 81,137,478 and 84,463,059 shares issued and outstandingas of June 30, 2025 and December 31, 2024, respectively | 81 | 84 |
| Additional paid-in capital | 799,951 | 802,770 |
| Accumulated other comprehensive gain | 37 | 233 |
| Accumulated deficit | (435,653) | (364,220) |
| Total stockholders’ equity | 364,416 | 438,867 |
| Total liabilities and stockholders’ equity | $391,605 | $464,668 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.